Sanofi's Chattem Acquires Rolaids Brand

Sanofi announces that its U.S. Consumer Healthcare Division, Chattem, Inc., completes the acquisition of the worldwide rights to the Rolaids brand from McNeil Consumer Healthcare Division of McNEIL-PPC, Inc.

 

"The addition of Rolaids represents a rare opportunity to obtain an iconic brand that we believe will respond positively to our proven approach of growing brands through innovation and advertising," says Zan Guerry, chief executive officer, Chattem. "We are primed to leverage the Rolaids market opportunity to drive incremental growth and take the brand to a new level."

 

Rolaids is an over-the-counter antacid that helps relieve heartburn and acid indigestion. The product was first introduced in 1954 and over the years it has been a top selling gastro-intestinal category brand. Chattem will re-launch Rolaids and expects the product to be available at retailers within a year.